XBRANE — Xbrane Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK235.93m
- SEK262.45m
- SEK152.35m
Brief: Xbrane Biopharma Q3 EBITDA SEK -6.6 Million
Brief: Xbrane Says FDA Approved Lucamzi
Sweden's Xbrane Biopharma posts Q2 net loss
Brief: Xbrane Biopharma Q2 EBITDA SEK -6.3 Million
Brief: Xbrane Biopharma, JOINN Biologics US Partner To Develop Xdarzane
Brief: Xbrane Gets FDA BsUFA Review Date
Brief: Xbrane, Partner Intas Agree On Revised Financing Arrangement
Brief: Venture Valuation Provides External Valuation Of Xdivane Program
Brief: Xbrane Biopharma Submits BLA To FDA For Lucentis Biosimilar Candidate
Sweden's Xbrane Q4 revenue falls sharply
Brief: Xbrane Biopharma Q4 Revenue Down At Sek 9.1 Million
Brief: Xbrane Biopharma To Issue 420,517 Warrants To Fenja
Brief: Xbrane Biopharma Q3 EBITDA Loss Sek 20.7 Mln
Brief: Xbrane Provides Regulatory Update On FDA Review
Brief: Xbrane Biopharma Enters Into SEK 60 Mln Financing Solution With Fenja
Brief: Xbrane Biopharma Q2 EBITDA SEK -3.6 Mln
Brief: Xbrane Raises SEK 240 Mln in Directed Share Issue
Brief: Onesource Specialty Pharma Proposes To Subscribe To Shares Of Xbrane Biopharma AB
Brief: Xbrane Says FDA To Decide On October 21st On Lucentis